What question did this study set out to answer?

To evaluate treatment strategies and long-term outcomes in patients with hairy cell leukemia (HCL) using real-world data.

December 8, 2025BloodOpen Access

Hairy cell leukemia treatment strategies: A real-world multicenter experience

View Full Paper

Ask AI

Bookmark

Authors

JFJames J. FradinMedical College of Wisconsin TBTalha BadarFroedtert Hospital

Discussion

Member takes

Implication

Retrospective cohort study reports treatment patterns and long-term outcomes in hairy cell leukemia, indicating high response rates with cladribine and rituximab.

Key Points

To evaluate treatment strategies and long-term outcomes in patients with hairy cell leukemia (HCL) using real-world data.
Multicenter retrospective cohort study
Included 104 adult patients diagnosed with HCL
Analyzed treatment patterns, response rates, overall survival (OS), and progression-free survival (PFS) from electronic medical records
Median overall survival was 24.5 years with a 5-year OS of 96.6%
Response rates to first-line therapies included 63% complete response for cladribine
High response rates observed with cladribine combined with rituximab, achieving 92% CR
Treatment-related hospitalizations occurred in 27% of patients for first-line therapy

Cite This Study

Fradin et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d287 https://doi.org/10.1182/blood-2025-1802

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reports treatment patterns and long-term outcomes in hairy cell leukemia, indicating high response rates with cladribine and rituximab.

Hairy cell leukemia treatment strategies: A real-world multicenter experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Hairy cell leukemia treatment strategies: A real-world multicenter experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider